A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome

NCT ID: NCT01008553

Last Updated: 2013-07-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 258 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-12-31
• Study Completion Date: 2010-03-31

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of fentanyl in opioid-naive participants with post-herpetic neuralgia, complex regional pain syndrome or post-operative pain syndrome who cannot obtain a sufficient analgesic effect by the treatment of non-opioid analgesics (drug used to control pain).

Detailed Description

This is a multi-center (conducted in more than one center), double-blind (neither the participant nor the physician knows the assigned study drug), randomized (participants assigned study drug by chance), withdrawal study in opioid-naive participants with post-herpetic neuralgia (intense, typically intermittent pain along the course of a nerve caused by the varicella zoster virus), complex regional pain syndrome or post-operative pain syndrome. The study will consist of titration period (10-29 days) and double-blind period (12 weeks) and the visits will include Day 5-7, 8, 15, 22, 29 in titration period and Day 2-4, 8, 15, 22, 29, 43, 57, 71 and 85 in double-blind period. All the eligible participants will receive one-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) of either fentanyl at the dose ranging from 12.5 to 50 microgram/hour or matching placebo. Efficacy will be evaluated primarily by time to withdrawal due to insufficient analgesic efficacy. Participants' safety will be monitored throughout the study.

Conditions

Postherpetic Neuralgia; Complex Regional Pain Syndromes (CRPS); Postoperative Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Fentanyl (Titration period)

One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will continue for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.

Group Type: EXPERIMENTAL

Fentanyl

Intervention Type: DRUG

One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Fentanyl (Double-blind period)

Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.

Group Type: EXPERIMENTAL

Fentanyl

Intervention Type: DRUG

One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Placebo (Double-blind period)

Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Interventions

Fentanyl

One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Intervention Type: DRUG

Placebo

Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participants whose pain because of post-herpetic neuralgia, Complex Regional Pain Syndrome (CRPS) or post-operative pain syndrome is continuing for at least 12 weeks prior to informed consent
• Participants who are continuously taking a non-opioid analgesic at the normal highest dose or more for at least 14 consecutive days prior to informed consent, or at a certain dose (except the use on an as-needed base) on consecutive days or participants who are continuously taking an analgesic adjuvant with a certain dosage and administration (except the use on an as-needed base) for at least 14 consecutive days prior to informed consent
• Participants showing insufficient therapeutic efficacy of the non-opioid analgesic currently being used, and to requiring a continuous opioid analgesic as per the Investigator or Sub-investigator
• Participants with an average pain intensity of 50 millimeter or more on the Visual Analog Scale in 24-hour daily living prior to informed consent
• Participants who can be hospitalized to the 4th day after the initiation of titration period

Exclusion Criteria

• Participants who had an operation that may affect the assessment within 30 days before informed consent
• Participants whose main cause of the pain to be assessed is considered attributable to psychogenic pain (physical pain that is caused, increased, or prolonged by mental, emotional, or behavioral factors)
• Participants with asthma, bradyarrhythmia (slow irregular heart beat) and severe respiratory function disorders
• Participants complicated with hepatic dysfunction such as fulminant hepatitis (inflammation of the liver) and liver cirrhosis (serious liver disorder in which connective tissue replaces normal liver tissue, and liver failure often occurs), or renal impairment such as nephritic syndrome, acute renal failure, and chronic renal failure
• Participants with a history of hypersensitivity to fentanyl and other opioid analgesics

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen Pharmaceutical K.K.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen Pharmaceutical K.K., Japan Clinical Trial

Role: STUDY_DIRECTOR

Janssen Pharmaceutical K.K.

Locations

Aichi, , Japan

Amagasaki, , Japan

Asahikawa, , Japan

Bunkyō City, , Japan

Chigasaki, , Japan

Chūō, , Japan

Ebetsu, , Japan

Fujieda, , Japan

Fujisawa, , Japan

Fukuoka, , Japan

Hakodate, , Japan

Hamamatsu, , Japan

Hatsukaichi, , Japan

Higashi-Kitami, , Japan

Hiratsuka, , Japan

Hirosaki, , Japan

Hiroshima, , Japan

Ichikawa, , Japan

Ikeda, , Japan

Isesaki, , Japan

Itabashi-Ku, , Japan

Izumo, , Japan

Kakegawa, , Japan

Kanazawa, , Japan

Kasama, , Japan

Kasuga, , Japan

Kawasaki, , Japan

Kita-Gun, , Japan

Kitakyushu, , Japan

Kitamoto, , Japan

Kobe, , Japan

Kochi, , Japan

Koga, , Japan

Komatsu, , Japan

Koshigaya, , Japan

Kyoto, , Japan

Maebashi, , Japan

Matsumoto, , Japan

Meguro City, , Japan

Miki, , Japan

Minato, , Japan

Miyazaki, , Japan

Moriguchi, , Japan

Morioka, , Japan

Nagasaki, , Japan

Nagoya, , Japan

Niihama, , Japan

Nishinomiya, , Japan

Obihiro, , Japan

Ohmura, , Japan

Ohta-Ku, , Japan

Ohtsu N/A, , Japan

Ohtsu, , Japan

Okayama, , Japan

Onomichi, , Japan

Osaka, , Japan

Saga, , Japan

Sakai, , Japan

Sapporo, , Japan

Sendai, , Japan

Setagaya City, , Japan

Shigenobu N/A, , Japan

Shimotsuga, , Japan

Shinagawa City, , Japan

Suita, , Japan

Suzaka, , Japan

Tamaho N/A, , Japan

Tokushima, , Japan

Tokyo, , Japan

Ube, , Japan

Urayasu, , Japan

Ureshino, , Japan

Wakayama, , Japan

Yachiyo, , Japan

Yamaguchi, , Japan

Yamanashi, , Japan

Yokohama, , Japan

Yonago, , Japan

Yūbari, , Japan

Countries

Japan

References

Arai T, Kashimoto Y, Ukyo Y, Tominaga Y, Imanaka K. Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-naive patients with chronic pain. Curr Med Res Opin. 2015 Dec;31(12):2207-18. doi: 10.1185/03007995.2015.1092127. Epub 2015 Oct 19.

Reference Type: DERIVED

PMID: 26359327 (View on PubMed)

Other Identifiers

JNS020QD-JPN-N02

Identifier Type: -

Identifier Source: secondary_id

CR015544

Identifier Type: -

Identifier Source: org_study_id